Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430082 | 0.92 | MAPT (0.55) | RAB9AHTTNPC1ALDH1A1MEN1 | |
| SCHEMBL14387007 | 0.92 | RAB9A (0.52) | RAB9AHTTNPY2RNPC1ALDH1A1 | |
| SCHEMBL14386902 | 0.92 | KMT2A (0.53) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14386893 | 0.90 | RAB9A (0.49) | RAB9AHTTNPY2RNPC1ALDH1A1 | |
| SCHEMBL14430080 | 0.90 | MEN1 (0.54) | RAB9ANPY2RNPC1ALDH1A1MEN1 | |
| SCHEMBL14430081 | 0.87 | LMNA (0.51) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14430084 | 0.87 | KMT2A (0.50) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14387010 | 0.87 | KMT2A (0.50) | RAB9AHTTNPC1ALDH1A1MEN1 | |
| SCHEMBL14430079 | 0.85 | KMT2A (0.48) | RAB9ANPY2RNPC1ALDH1A1MEN1 | |
| SCHEMBL14430083 | 0.84 | KMT2A (0.53) | RAB9ANPY2RNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | RAB9A 3799/4885HTT 3762/4885NPY2R 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.